Aim: In view of the increasing prevalence of obesity in adolescents, the aim of this study was to determine the pharmacokinetics of the CYP3A substrate midazolam and its metabolites in overweight and obese adolescents.
Methods: Overweight (BMI for age ≥ 85(th) percentile) and obese (BMI for age ≥ 95(th) percentile) adolescents undergoing surgery received 2 or 3 mg intravenous midazolam as a sedative drug pre-operatively. Blood samples were collected until 6 or 8 h post-dose. Population pharmacokinetic modelling and systematic covariate analysis were performed using nonmem 7.2.
Results: Nineteen overweight and obese patients with a mean body weight of 102.7 kg (62-149.8 kg), a mean BMI of 36.1 kg m(-2) (24.8-55 kg m(-2)), and a mean age of 15.9 years (range 12.5-18.9 years) were included. In the model for midazolam and metabolites, total body weight was not of influence on clearance (0.66 l min(-1) (RSE 8.3%)), while peripheral volume of distribution of midazolam (154 l (11.2%)), increased substantially with total body weight (P < 0.001). The increase in peripheral volume could be explained by excess body weight (WTexcess ) instead of body weight related to growth (WTfor age and length ).
Conclusions: The pharmacokinetics of midazolam and its metabolites in overweight and obese adolescents show a marked increase in peripheral volume of distribution and a lack of influence on clearance. The findings may imply a need for a higher initial infusion rate upon initiation of a continuous infusion in obese adolescents.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4631191 | PMC |
| http://dx.doi.org/10.1111/bcp.12693 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Demographic-Based Personalized Left Ventricular Hypertrophy Thresholds for Hypertrophic Cardiomyopathy Diagnosis.
J Am Coll Cardiol
December 2024
Barts Heart Centre, Barts Health NHS Trust, West Smithfield, London, United Kingdom; Institute of Cardiovascular Science, University College London, London, United Kingdom.
Background: Hypertrophic cardiomyopathy (HCM) is a leading cause of sudden cardiac death. Current diagnosis emphasizes the detection of left ventricular hypertrophy (LVH) using a fixed threshold of ≥15-mm maximum wall thickness (MWT). This study proposes a method that considers individual demographics to adjust LVH thresholds as an alternative to a 1-size-fits-all approach.
View Article and Find Full Text PDFCost-Effectiveness of Semaglutide in Patients With Obesity and Cardiovascular Disease.
Can J Cardiol
December 2024
Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada; Department of Medicine, University of Calgary, Calgary, Alberta, Canada; O'Brien Institute for Public Health, University of Calgary, Calgary, Alberta, Canada; Department of Cardiac Sciences, University of Calgary, Calgary, Alberta, Canada. Electronic address:
Background: Randomized clinical trials have shown that semaglutide is associated with a clinically relevant reduction in body weight and a lower risk of adverse cardiovascular events in those who are overweight or obese with a history of cardiovascular disease but no diabetes. The objective of this study was to assess the cost-effectiveness of semaglutide for this indication.
Methods: A decision analytic Markov model was used to compare the lifetime benefits and costs of semaglutide 2.
[Not Available].
Postepy Biochem
December 2024
Department of Molecular Microbiology, Institute of Microbiology, Faculty of Biology, University of Warsaw.
Mikrobiota układu pokarmowego jest nieodzownym elementem właściwego funkcjonowania organizmu człowieka, bowiem drobnoustroje jelitowe i ich metabolity silnie wpływają na metabolizm gospodarza i funkcje odpornościowe, jak również przyczyniają się do biosyntezy witamin, produkcji hormonów jelitowych, utrzymania integralności bariery jelitowej i ochrony przed patogenami, a także trawienia i wchłaniania składników odżywczych. Coraz częściej podkreśla się istnienie zależności pomiędzy zaburzeniami składu mikrobioty jelit a pojawianiem się chorób metabolicznych, tj. otyłości czy cukrzycy typu 2.
View Article and Find Full Text PDFInterim Analysis of a Prospective Polysomnographic Study of Weighted Blankets in Patients with Psychophysiological Insomnia.
Psychiatry Clin Psychopharmacol
December 2024
Sleep and Disorders Unit, Division of Clinical Neurophysiology, Department of Neurology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, İstanbul, Türkiye.
Background: Weighted blankets have recently introduced in the treatment on insomnia as a nonpharmacological integrative therapy. Here we prospectively evaluated the effects of weighted blankets on the sleep structure and heart rate variability (HRV) in patients with primary psychophysiological insomnia.
Methods: In this prospective polysomnographic (PSG) study between August 2021 and August 2022, patients were given weighted blankets (~10% of body weight) to use at home for 10 nights consecutively.
Development of a Population Pharmacokinetic Gabapentin Model Leveraging Therapeutic Drug Monitoring Concentrations.
Pharmaceutics
November 2024
Department of Pharmacy Practice, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, 160 Frelinghuysen Road, Piscataway, NJ 08854, USA.
Gabapentin has variable pharmacokinetics (PK), which contributes to difficulty in dosing and increased risk of adverse events. The objective of this study was to leverage gabapentin concentrations from therapeutic drug monitoring (TDM) to develop a population PK (popPK) model and characterize significant covariates that impact gabapentin PK. Data were retrospectively collected from 82 hospitalized adult patients with TDM gabapentin concentrations.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!